After this buyout, there are some articles quoting analysts about their best guesses on other takeout targets.
Here's one such:
Citi munch targets
OPHT, PBTI, LXRX, ARDX, RARE, and VSAR.
OPHT looks fairly expensive already. Maybe you follow them a little, as they will be competing with REGN (among others) in AMD? I also kicked the tires on ARDX. I don't think there's much clinical or regulatory risk with that one, but not sure if their drugs are sufficiently differentiated to make it commercially. They own all their drugs and are open to partnering, having had their lead drug for IBS-c and hyperphosphatemia returned by Astra a while back. The inherent diarrheic effect of its MOA makes it a better candidate for IBS-c, IMO. But not sure if it will be sufficiently differentiated from Linzess. At least ARDX is not competing against generics with such marginal advantages.
I haven't followed LXRX in ages. It's had a nice run, but its pipe still looks interesting for the price; their diabetes candidate (dual GLP1&2 inhibitor) looks superficially promising.
Anyone follow these? Have opinions on their munchability?
INCY, SGEN, BMRN also getting chatter, but that's not new to us.
Cheers, Tuck |
